Product Information
ORILISSA 150 MG TABLET is a brand product labeled by AbbVie Inc., priced at $43.8196 per EA under NDC 00074003828. Its NADAC has been published 396 times since Jan 23, 2019.
FDA first approved this application on Jul 23, 2018.
Strength
150 mg/1
Manufacturer
AbbVie Inc.NDC
00074003828
Classification
Brand
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
ELAGOLIX SODIUMApproval Type
New Drug (NDA)
FDA Application
NDA210450FDA Approved
7/23/2018
On Market Since
7/23/2018
Pharmacological Classes
Price Statistics
The NADAC for ORILISSA 150 MG TABLET has been published 396 times since Jan 23, 2019, and over the history we have for it it has risen 49.5%. The table below summarizes its recorded NADAC range and movement.
| Current price | $43.8196 per EA |
|---|---|
| All-time high | $43.8196 (Aug 19, 2026) |
| All-time low | $28.9809 (Nov 20, 2019) |
| 52-week high | $43.8196 |
| 52-week low | $41.7051 |
| Median price | $36.1525 |
| Average price | $36.3324 |
| Largest weekly change | +7.4% (Jan 8, 2020) |
| Weeks tracked | 396 |
| Tracking since | Jan 23, 2019 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Elagolix market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of ORILISSA 150 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ORILISSA 150 MG TABLET, manufactured by AbbVie Inc., is $43.8196 per EA (NDC 00074003828), effective Aug 19, 2026.
How has the price of ORILISSA 150 MG TABLET changed over time?
Over the history we have for it, the NADAC for ORILISSA 150 MG TABLET has risen 49.5%. It has been tracked across 396 weekly CMS publications since Jan 23, 2019.
What are the highest and lowest recorded NADAC prices for ORILISSA 150 MG TABLET?
Since Jan 23, 2019, the NADAC for ORILISSA 150 MG TABLET has ranged from a low of $28.9809 (Nov 20, 2019) to a high of $43.8196 (Aug 19, 2026), with a median of $36.1525 per EA.
Are there cheaper alternatives to ORILISSA 150 MG TABLET?
No other NADAC-published product currently shares the active ingredient and strength of ORILISSA 150 MG TABLET in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures ORILISSA 150 MG TABLET?
ORILISSA 150 MG TABLET (NDC 00074003828) is labeled by AbbVie Inc., and CMS classifies it as a brand product.